Treatment of carotid artery dissection with elevated risk of extracranial or intracranial hemorrhage
Cervical artery dissection complicated by an elevated hemorrhage risk demands a carefully considered antithrombotic strategy — one that differs from the standard approach used in lower-risk presentations.
This protocol applies to patients with cervical artery dissection who carry an elevated risk of extracranial hemorrhage or intracranial hemorrhage. Risk features include large infarct size, hemorrhagic transformation, and intradural extension of extracranial dissection. Each of these factors shifts the benefit-risk balance of antithrombotic treatment and warrants specific management guidance.
When judged clinically safe, antiplatelet therapy forms the basis of antithrombotic management in this hemorrhage-risk setting. The duration of treatment is bounded by evidence-based parameters. The complete protocol — including agent selection criteria, sequencing options, and the full duration framework — is available via the link below.
References
DOI: 10.1161/STR.0000000000000457
Patients without radiographic high-risk features or those with an elevated risk of extracranial hemorrhage or ICH (eg, large infarct size, hemorrhagic transformation, intradural extension of extracranial dissection) may be better suited for antiplatelet therapy, with either antiplatelet monotherapy or a short course of dual antiplatelet therapy for 21 to 90 days (in line with minor stroke/TIA and CADISS) if considered safe, followed by single antiplatelet therapy.
It is reasonable that the duration of antithrombotic therapy in patients with cervical artery dissection be 3–6 mo.
View source ↗